Eli Lilly and Company (LLY)

NYSE: LLY · Real-Time Price · USD
826.41
+0.96 (0.12%)
At close: Oct 27, 2025, 4:00 PM EDT
827.05
+0.64 (0.08%)
Pre-market: Oct 28, 2025, 5:51 AM EDT
0.12%
Market Cap741.90B
Revenue (ttm)53.26B
Net Income (ttm)13.80B
Shares Out 897.74M
EPS (ttm)15.29
PE Ratio54.04
Forward PE30.35
Dividend$6.00 (0.73%)
Ex-Dividend DateAug 15, 2025
Volume2,114,752
Open825.00
Previous Close825.45
Day's Range811.48 - 826.42
52-Week Range623.78 - 935.63
Beta0.46
AnalystsStrong Buy
Price Target969.56 (+17.32%)
Earnings DateOct 30, 2025

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $969.56, which is an increase of 17.32% from the latest price.

Price Target
$969.56
(17.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh single-injection dosing will be available for U.S. patient...

13 hours ago - PRNewsWire

Lilly declares fourth-quarter 2025 dividend

INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common...

15 hours ago - PRNewsWire

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...

Other symbols: ARGXBSXINSMISRGRDNT
16 hours ago - Seeking Alpha

LLY Stock To $1,100?

Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca si...

20 hours ago - Forbes

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its burde...

23 hours ago - PRNewsWire

Eli Lilly: Is Another Monster Quarter Coming

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stoc...

1 day ago - Seeking Alpha

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adver...

Other symbols: ADVM
2 days ago - Business Wire

Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 million, aiming to strengthen its pipeline with an experimental eye disease tr...

Other symbols: ADVM
3 days ago - Reuters

Eli Lilly: Time To Buy LLY Stock?

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, o...

3 days ago - Forbes

Lilly to Acquire Adverum Biotechnologies

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly'...

Other symbols: ADVM
3 days ago - PRNewsWire

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncerta...

3 days ago - Benzinga

Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema.

3 days ago - Reuters

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials  New data show ...

Other symbols: INCY
3 days ago - PRNewsWire

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance d...

3 days ago - PRNewsWire

10 stocks primed for growth in the S&P 500's cheapest sectors

Even a slow-growing sector can include rapidly growing companies that are putting up big numbers

4 days ago - Market Watch

Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats

Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. ...

Other symbols: NVO
4 days ago - Seeking Alpha

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.

4 days ago - Reuters

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...

7 days ago - Seeking Alpha

Our Top 10 High Growth Dividend Stocks - October 2025

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...

Other symbols: ALAPHAVGOBKCOFEMEFIX
9 days ago - Seeking Alpha

President Trump targets $150 MFN price for GLP-1s

Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1...

Other symbols: NVO
10 days ago - CNBC Television

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th...

Other symbols: NVO
10 days ago - CNBC

3 Price Catalysts For Eli Lilly

Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or...

10 days ago - Seeking Alpha

Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks

Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Li...

Other symbols: NVO
10 days ago - Investopedia

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...

Other symbols: PFE
10 days ago - Benzinga

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the P...

10 days ago - PRNewsWire